SunTrust Banks Weighs in on Charles River Laboratories Intl. Inc’s Q1 2018 Earnings (CRL)

Charles River Laboratories Intl. Inc (NYSE:CRL) – SunTrust Banks issued their Q1 2018 EPS estimates for shares of Charles River Laboratories Intl. in a report issued on Wednesday. SunTrust Banks analyst S. Draper anticipates that the medical research company will post earnings per share of $1.24 for the quarter. SunTrust Banks currently has a “Buy” rating and a $125.00 price objective on the stock. SunTrust Banks also issued estimates for Charles River Laboratories Intl.’s Q2 2018 earnings at $1.41 EPS, Q3 2018 earnings at $1.38 EPS, Q4 2018 earnings at $1.48 EPS, FY2018 earnings at $5.51 EPS and FY2019 earnings at $6.06 EPS.

A number of other equities analysts also recently weighed in on CRL. Credit Suisse Group reiterated a “hold” rating and issued a $108.00 target price on shares of Charles River Laboratories Intl. in a report on Thursday. Royal Bank of Canada set a $116.00 target price on Charles River Laboratories Intl. and gave the company a “hold” rating in a report on Tuesday. TheStreet downgraded Charles River Laboratories Intl. from an “a-” rating to a “c+” rating in a report on Tuesday. JPMorgan Chase & Co. upped their target price on Charles River Laboratories Intl. from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Robert W. Baird set a $123.00 target price on Charles River Laboratories Intl. and gave the company a “buy” rating in a report on Tuesday. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $114.85.

Shares of Charles River Laboratories Intl. (NYSE:CRL) opened at $110.31 on Thursday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.62 and a current ratio of 1.78. The stock has a market capitalization of $5,106.20, a PE ratio of 43.43, a price-to-earnings-growth ratio of 1.60 and a beta of 0.74. Charles River Laboratories Intl. has a twelve month low of $86.25 and a twelve month high of $119.05.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings data on Tuesday, February 13th. The medical research company reported $1.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.26 by $0.14. The firm had revenue of $478.50 million for the quarter, compared to the consensus estimate of $475.02 million. Charles River Laboratories Intl. had a return on equity of 26.14% and a net margin of 6.64%. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.21 EPS.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC grew its stake in shares of Charles River Laboratories Intl. by 1,071.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,054 shares of the medical research company’s stock valued at $115,000 after buying an additional 964 shares in the last quarter. YorkBridge Wealth Partners LLC grew its stake in shares of Charles River Laboratories Intl. by 445.5% in the 3rd quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock valued at $118,000 after buying an additional 891 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. grew its stake in shares of Charles River Laboratories Intl. by 69.0% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock valued at $145,000 after buying an additional 548 shares in the last quarter. Advisor Group Inc. boosted its position in Charles River Laboratories Intl. by 159.4% during the third quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock worth $165,000 after purchasing an additional 945 shares during the period. Finally, Zions Bancorporation bought a new stake in Charles River Laboratories Intl. during the third quarter worth approximately $212,000. 97.13% of the stock is owned by institutional investors and hedge funds.

In related news, Director C Richard Reese sold 10,227 shares of the business’s stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $102.40, for a total value of $1,047,244.80. Following the completion of the sale, the director now owns 51,444 shares of the company’s stock, valued at approximately $5,267,865.60. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Robert J. Bertolini sold 3,609 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $110.22, for a total value of $397,783.98. The disclosure for this sale can be found here. In the last three months, insiders sold 195,673 shares of company stock valued at $2,644,046. 2.20% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/15/suntrust-banks-weighs-in-on-charles-river-laboratories-intl-incs-q1-2018-earnings-crl.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply